Camrelizumab, initially known as SHR-1210, represents a significant advancement in malignant treatment, functioning as a monoclonal that targets the programmed cell death 1 receptor. This checkpoint protein, https://ztndz.com/story28350471/camrelizumab-shr-1210-a-deep-analysis-into-the-pd-1-blocking-treatment